As the JAK2/p-STAT3 pathway is a classic inflammatory pathway involved in tumor progression, we subsequently explored the effects of ALKBH5 on JAK2/p-STAT3 signaling in NSCLC. Here, JAK2 is linked to non-small cell lung carcinoma.